Combinatorial therapy targeting PD-L1 pathway enhances the efficacy of Cancer immunotherapy in Glioblastoma: A therapeutic mix encompassing Niclosamide, Curcumin, Chlorpromazine, Procainamide, IP-504, and Salinomycin inhibits oncoproteins EGFR, and Bcl-xl expression, increases tumor suppressor p53 expression, inhibits glioblastoma proliferation, increases interferon-IFNγ signaling, increase antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival via up-regulation of its target gene, 16/October/2018, 12.42 pm